Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Table 3 Comparison of neoadjuvant trials in lung cancer

Trial	Phase	TNM	Population	Regimen	Sample	RR
Chemotherapy
Roth 1994 [21]	II	IIIA	Total	CEP	28	35 %
Rosell 1994 [20]	II	IIIA	Total	MIC	30	–
Scagliotti 2012 [19] (CHEST)	III	I-IIIA	Total	GC	129	35.4 %
TKI
Lara-Guerra 2009 [13]	II	I	Total	G	36	11 %
	II	I	Mut EGFR	G	6	50 %
Schaake 2012 [14]	II	I-IIIA	Total	E	60	5 %
	II	I-IIIA	Enriched	E	29	34 %
Chemo-TKI
Lu 2013 [22] (CTONG 1101)	II	IIIA-N2	Enriched	E + GC	39	46 %
Bio-maker guided
Zhong 2014 (CSLC 0702)	II	IIIA-N2	Total	E or GC	24	42 %
	II	IIIA-N2	Mut EGFR	E	12	58.3 %
	II	IIIA-N2	WT-EGFR	GC	12	25 %

CEP cyclophosphamide/etoposide/cisplatin, MIC mitomycin/ifosfamide/cisplatin, GC gemcitabine/carboplatin, E erlotinib, G gefitinib, TKI tyrosine kinase inhibitor, RR response rate, EGFR epidermal growth factor receptor, Mut mutant, WT wild type

ISSN: 1756-8722